The management of castration-resistant prostate cancer (CRPC) remains a significant clinical challenge. Prostate-specific membrane antigen (PSMA)-PET/CT imaging has changed diagnostic assessment an...
<p><strong>Tác giả:</strong> Surilige, Jiacheng Liang, Ruimin Ren</p>
<p>The management of castration-resistant prostate cancer (CRPC) remains a significant clinical challenge. Prostate-specific membrane antigen (PSMA)-PET/CT imaging has changed diagnostic assessment and treatment selection in CRPC because of its high lesion-detection capability in selected settings, and has spurred novel therapies such as PSMA-targeted radioligand therapy (RLT). However, the marked heterogeneity in PSMA expression poses a central obstacle to precision medicine. It can contribute...</p>
<p>📄 DOI: <a href="https://doi.org/https://doi.org/10.3389/fonc.2026.1956272" target="_blank" rel="noopener">https://doi.org/10.3389/fonc.2026.1956272</a></p>
<p>📖 <a href="https://doi.org/https://doi.org/10.3389/fonc.2026.1956272" target="_blank" rel="noopener">Xem bài báo đầy đủ</a></p>
Bài viết được biên soạn lại bởi LIFVietnam. Nguồn tham khảo: OpenAlex
